Courage to innovate
Change the future

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

OBI Pharma, Inc. (4174.TWO), a clinical-stage oncology company, announced that OBI-992, a TROP2 targeted antibody-drug conjugate (ADC), has been shortlisted from over 1,000 nominations submitted as one of the eight “2024 Most Promising Clinical Candidate” by the 11th Annual World ADC Awards.  The World ADC Awards were created 11 years ago to commemorate scientific excellence […]

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme – EndoSymeOBI® – for ADCs

OBI Pharma (4174.TWO) presented the results of its patented enzyme, EndoSz, used to power the exclusive glycan-based ADC platform GlycOBI®, at the 2nd World ADC Linker & Conjugation Summit held in Boston, Massachusetts August 20-22, 2024. EndoSz is an enzyme derived from Streptococcus equi subsp. zooepidemicus Sz105, also known as endo-β-N-acetylglucosaminidase. OBI Pharma has obtained […]

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

OBI Pharma, a clinical-stage oncology company (4174.TWO), received the notification letter today from US FDA, stating that the request for Orphan Drug Designation of OBI-992 TROP2 ADC for the treatment of gastric cancer, including gastroesophageal junction cancer, has been approved. Heidi Wang, Ph.D, OBI Pharma’s Chief Executive Officer pointed out, the U.S. FDA grants Orphan […]

OBI ‘s Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.

OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme in the field of new drug development. OBI Pharma’s proprietary enzyme, EndoSymeOBI™, recently being featured on the cover of the JACS Au. This recognition underscores the promising potential of the enzyme […]

Dr. Heidi Wang, CEO of OBI Pharma, Inc., Selected as One of the Top 10 Managers of High-performing Enterprises by the Golden Torch Award

Taipei, Taiwan – The Golden Torch Award, a prestigious program that honors outstanding corporate leaders, announced today (June 21) that Dr. Heidi Wang, CEO of OBI Pharma, Inc. (4174.two), has been selected as one of the “Top 10 Managers of High-performing Enterprises”. Dr. Wang holds a Ph.D. in Molecular Biology and Virology from the University […]

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation 

Strong emphasis on developing ADC assets and technology platform and encouraging global collaborations and partnership   OBI PHARMA, INC. (4174 TWO ) has undergone meaningful transformation over the past year. From pipeline refresh, organizational restructuring, to cultural revitalization, the company’s commitment to innovation is evident. Dr. Heidi Wang, CEO of OBI, emphasizes that this transformation […]

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy

Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. TAIPEI, Taiwan, June 12, 2024, ─ OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor […]

2024 Annual Shareholders’ Meeting

OBI Pharma at BIO USA 2024

OBI showcased its proprietary ADC platform GlycOBI™ and attracted significant interest from the audience significant interest from the audience On June 4th, OBI Pharma from Taiwan made a notable appearance at BIO USA 2024. The company introduced its proprietary ADC (Antibody-Drug Conjugate) technology platform, GlycOBI™, which quickly garnered significant interest. This platform enables site-specific conjugation […]

2024 ASCO Annual Meeting